Asbestos, ergot drugs and the pleura

Authors:
  • PVP De Vuyst
    P De Vuyst
  • PPP Pfitzenmeyer
    P Pfitzenmeyer
  • PCP Camus
    P Camus

Abstract
In this issue of the Journal, two groups of researchers with established experience in asbestos-induced respira- tory disease, independently report on patients with prior occupational exposure to asbestos, who developed exuda- tive pleural effusion and/or pleural thickening, while be- ing treated with bromocriptine for Parkinson's disease (1, 2). Ultimately, the pleural changes were largely rever- sible following drug withdrawal. Both groups prudently stressed that, since no control group was included, the interaction of, and possible potentiation between asbestos and ergot drugs currently remains speculative (1, 3). Des- pite the lack of definitive epidemiological evidence that bromocriptine and asbestos act synergistically to induce pleural thickening, fibrosis or effusion, the Editorial Board of the Journal decided to have these papers published, as a possible warning sign in occupational/iatrogenic respira- tory disease. The following pleural lesions are associated with as- bestos exposure: hyaline or calcified plaques of the pari- etal pleura; diffuse pleural thickening or fibrosis involving the visceral pleura; benign exudative or haemorrhagic effusions; and the malignant mesothelioma (4-7). The typical radiographic manifestations of asbestos-induced pleural lesions are distinctive (5, 6), but the diagnosis of early mesothelioma in patients with pleural thickening may be difficult. Classically, folding and shrinking of the lung, and rounded atelectasis (8-12) are ascribed to fibro- sis of the visceral pleura. Benign asbestos pleural effusion may be followed by pleural thickening or fibrosis, but rarely by the development of pleural mesothelioma (13).

This publication has 22 references indexed in Scilit: